Q32 Bio Inc. — Director's Dealing 2018

Mar 27, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2018-03-27

Reporting Person: SHAH MAHENDRA (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Preferred Stock	$		Common Stock (659742)		Indirect

Footnotes

F1: The preferred stock will automatically convert into the Issuer's common stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F2: The securities reported herein are held of record by Vivo Panda Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D., is a managing member of Vivo LLC and has shared voting and investment power over the shares beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the Series B Preferred Stock held directly by Vivo LP. Each of Vivo LLC and Dr. Shah disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.